Citigroup upgraded shares of Icon (NASDAQ:ICLR – Free Report) to a hold rating in a report issued on Thursday morning,Zacks.com reports.
Several other equities research analysts also recently issued reports on the company. Weiss Ratings downgraded Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. JPMorgan Chase & Co. boosted their price objective on Icon from $130.00 to $155.00 and gave the stock a “neutral” rating in a research report on Thursday, June 25th. Royal Bank Of Canada raised Icon from a “sector perform” rating to an “outperform” rating and raised their target price for the company from $126.00 to $185.00 in a report on Thursday, June 25th. Robert W. Baird set a $194.00 price target on Icon in a research report on Friday. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $165.00 price target on shares of Icon in a report on Friday, May 29th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $170.40.
Icon Price Performance
Icon (NASDAQ:ICLR – Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical research company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.55 by $0.01. The firm had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the firm posted $3.26 EPS. On average, sell-side analysts predict that Icon will post 9.43 EPS for the current year.
Institutional Investors Weigh In On Icon
Hedge funds have recently made changes to their positions in the stock. Harris Associates L P acquired a new stake in Icon during the second quarter worth about $238,256,000. Capital World Investors raised its holdings in Icon by 555.2% in the 4th quarter. Capital World Investors now owns 1,496,479 shares of the medical research company’s stock valued at $272,688,000 after acquiring an additional 1,268,095 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Icon by 26.6% in the 3rd quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock worth $811,499,000 after acquiring an additional 975,268 shares during the period. Lyrical Asset Management LP bought a new stake in shares of Icon in the 4th quarter worth approximately $176,382,000. Finally, Norges Bank acquired a new stake in shares of Icon during the 4th quarter worth approximately $160,073,000. Institutional investors own 95.61% of the company’s stock.
Icon News Roundup
Here are the key news stories impacting Icon this week:
- Positive Sentiment: Truist reaffirmed its “Buy” rating and raised its price target to $209 from $207, implying substantial upside based on the referenced share price. The target increase signals continued confidence in Icon’s long-term growth prospects. Benzinga analyst rating report
- Positive Sentiment: Icon reported second-quarter revenue of approximately $2.06 billion, above the roughly $2.00 billion consensus estimate, with revenue growing 2.3% from the prior-year period. The earnings call also emphasized a strong surge in bookings, supporting future revenue visibility. Q2 2026 earnings call highlights
- Positive Sentiment: Zacks upgraded ICLR from “Strong Sell” to “Hold,” suggesting its view has improved even though the firm remains cautious. Zacks rating update
- Neutral Sentiment: Quarterly adjusted EPS was $2.56, narrowly above some consensus estimates of $2.55, although another Zacks estimate was $2.57. The mixed comparison makes the earnings beat less decisive for investors. Icon Q2 earnings snapshot
- Negative Sentiment: EPS fell sharply from $3.26 a year earlier, while the earnings call highlighted margin pressures. The weaker profitability, despite higher revenue and bookings, is likely the main factor tempering the bullish analyst commentary. ICON Q2 2026 earnings call transcript
Icon Company Profile
Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.
Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.
Featured Articles
- Five stocks we like better than Icon
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
- MarketBeat Week in Review – 07/27- 07/31
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.
